Core Viewpoint - Tuoxin Pharmaceutical, established in 2005 and listed in 2021, is a leading domestic manufacturer of nucleoside raw materials with significant technological advantages in research and production, presenting investment value [1] Group 1: Business Performance - In Q3 2025, Tuoxin Pharmaceutical reported revenue of 272 million yuan, ranking 41st out of 47 in the industry, while the industry leader, Prolo Pharmaceutical, achieved 7.764 billion yuan [2] - The net profit for the same period was -30.16 million yuan, also ranking 41st, with the industry average net profit being 133 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 9.89%, lower than the previous year's 10.17% and significantly below the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 29.36%, an increase from 25.69% year-on-year, but still below the industry average of 35.38% [3] Group 3: Executive Compensation - Chairman Yang Xining's salary for 2024 is 1.0063 million yuan, a decrease of 20,300 yuan from 2023 [4] - President Yang Shaohua's salary for 2024 is 605,100 yuan, an increase of 164,200 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.18% to 18,100, while the average number of circulating A-shares held per account decreased by 9.75% to 4,988.97 [5]
拓新药业的前世今生：2025年三季度营收2.72亿排41名，净利润-3016.11万排41名，资产负债率远低于行业平均